Fundraising Fox
Arcturus Therapeutics
NASDAQ: ARCTSan Diego, US · Founded 2013 · Incorporated in Delaware · 1 known investors
Find your way into Arcturus Therapeutics
Sign up to find every way you can get introduced to Arcturus Therapeutics
- Your email: who you already know at Arcturus Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Arcturus Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Arcturus develops messenger RNA therapeutics and vaccines targeting rare genetic diseases and infectious pathogens, including a self-amplifying mRNA COVID-19 vaccine approved in Japan and Europe, along with clinical-stage candidates for cystic fibrosis and ornithine transcarbamylase deficiency.
Founders & leadership
Arcturus Therapeutics was founded in 2013 by Pad Chivukula and Padmanabh Chivukula.
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$73.7M disclosed across 2 rounds · 2014–2017
▶$67.8MraisedJan 2018 · 82 investors · BiotechnologyRule 506(b)
- David ShapiroDirector
- Stuart CollinsonDirector
- Pad ChivukulaExecutive Officer, Director
- Craig WillettDirector
- Orli ToriDirector
- Joseph E PayneExecutive Officer, Director
- Daniel GeffkenDirector
- Offering amount
- $67.8M
- Amount sold
- $67.8M
- Sales commissions
- $950K
- First sale
- Nov 2017
- Incorporated
- Other, Israel
- Federal exemptions
- 06b
▶$5.9MraisedOct 2015 · 43 investors · BiotechnologyRule 506(b)
- Craig WillettDirector
- Joseph Edward PayneExecutive Officer, Director
- Padmanabh ChivukulaExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $5.9M
- First sale
- Oct 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Arcturus Therapeutics do?
- Arcturus develops messenger RNA therapeutics and vaccines targeting rare genetic diseases and infectious pathogens, including a self-amplifying mRNA COVID-19 vaccine approved in Japan and Europe, along with clinical-stage candidates for cystic fibrosis and ornithine transcarbamylase deficiency.
- Who founded Arcturus Therapeutics?
- Arcturus Therapeutics was founded by Pad Chivukula, Padmanabh Chivukula in 2013.
- Who are Arcturus Therapeutics's investors?
- Arcturus Therapeutics's investors include Khosla Ventures.
- How much funding has Arcturus Therapeutics raised?
- Arcturus Therapeutics has disclosed $73.7M raised across 2 rounds.
- Where is Arcturus Therapeutics headquartered?
- Arcturus Therapeutics is headquartered in San Diego, US.